Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Growth hormone is not the answer.

April 17, 2010

Analysis of:Growth hormone not beneficial for ALS | pharmalive.com

1. I agree, growth hormone is not the answer. 2. ALS is due to progressive degeneration of motor neurons, specifically. I don't think a lack of growth hormone is the primary cause.

I am worried about patient privacy too

April 17, 2010

Analysis of:Google Reveals Plans for Personal Health Record Platform | www.cio.com

1. Patient privacy cannot be protected.2. Such private information can be subject to abuse and be harmful to that patient.3. Physicians will not be held responsible for this; the HIPAA law would be completely disregarded.

a natural response by competitor

October 26, 2009

Analysis of:Boehringer Ingelheim receives approval from the European Commission for Mirapexin®/Sifrol® prolonged-release, once daily tablet for the treatment of Parkinson`s disease | www.pipelinereview.com

1. Requip XL will be coming out soon so BI had to come up with Mirapex once daily SR.2. Once daily dosing is probably better for our Parkinson's patients as this will provide continuous dopaminergic stimulation with less fluctuation.

we already have sumatriptan

August 14, 2009

Analysis of:Orchid gets USFDA approval for migraine drug | economictimes.indiatimes.com

I read the article re 'Orchid gets USFDA approval for migraine drug'. This refers to Sumatriptan, 25mg, 50mg and 100mg.

Too early to tell, let's see

March 23, 2009

Analysis of:New Alzheimer's disease drugs available with five years | www.nursingtimes.net

It's still too early to tell, let's see how things go. The article mentions medications that slow down the progression of Alzheimer's, but this is already what the current medications are doing. We need medications that can reverse the process. In early stages of Alzheimer's I've seen some patients on Aricept acheive this, only to slide back in about 5 years.

Good prelim data but need to wait for further data

December 28, 2008

Analysis of:Multiple Sclerosis - FTY720 (Fingolimod) Trial Results | www.medicalnewstoday.com

1. There is a significant difference among relapse rates btw patients on Avonex vs Fingolimod. 2. Need to see what the dropout rate was and why, what side effects occurred with Fingolimod. 3. MS is a chronic disorder thus need long term data in future.

The trial will go well, but what are we trying to achieve?

December 28, 2008

Analysis of:Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease | pharmalive.com

I think the trial will go well, but what are we trying to achieve? Remember this medication first came out in Russia, and although been proven(most likely) superior to placebo, the big question is 1. Will it be more effective than the current meds here in the US(Aricept, Namenda, etc)? I have seen a fair number of Alzheimer pts who on Aricept have IMPROVEMENT of mini mental status exam scores and functionality if taken early. Dimebon will have to prove to be superior to these meds to have any consideration at all for pts to switch to this med. 2. Another factor(determining which product will have the majority of Alzheimer's pts, which number will grow astronomically in the next several decades) is COST: soon Aricept, Namenda will become generic; in this population(retired, on limited financial sources and some in the infamous doughnut hole) it would be hard(and unethical) to switch a pt from a cheaper, generic med to an expensive, brand one if effects are comparable.

Growth hormone is not the answer.

December 28, 2008

Analysis of:Growth hormone not beneficial for ALS | pharmalive.com

1. I agree, growth hormone is not the answer. 2. ALS is due to progressive degeneration of motor neurons, specifically. I don't think a lack of growth hormone is the primary cause.

Page : 11 to 8 of 8

Subscribe to Updates

By RSS